Table 3.
Duration of exposure
| Duration of exposure | OROS hydromorphone ER (N = 447) |
|---|---|
| Duration, daysa | |
| Mean (SD) | 20.1 (9.58) |
| Median (range) | 22.0 (1–49) |
| Duration rangeb, n (%) | |
| <1 week | 34 (7.6) |
| 1 to <2 weeks | 75 (16.8) |
| 2 to <3 weeks | 97 (21.7) |
| 3 to <4 weeks | 107 (23.9) |
| ≥4 weeksc | 134 (30.0) |
Notes:
a
Duration in days calculated as the difference between the first date medication was dispensed and the date of the last dose in the conversion and titration phase;
b
duration in weeks calculated as the difference between the first date medication was dispensed and the date of the last dose in the conversion and titration phase divided by seven;
c
last office visit, if necessary, occurred at week 4/day 29.
Abbreviations: ER, extended release; N, total number; SD, standard deviation.